Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immunotech Biopharm Ltd ( (HK:6978) ) has provided an update.
Immunotech Biopharm Ltd has placed RMB50 million into a principal-protected, floating-income structured deposit with SPD Bank, tying returns to movements in the EUR/USD spot exchange rate. The 29-day product, effective 2 March 2026 and maturing 31 March 2026, offers an annualized return ranging from a minimum of 0.70% to as high as 2.2%, depending on exchange-rate performance against a Bloomberg BFIX benchmark.
The transaction crosses the 5% threshold under Hong Kong Listing Rules, classifying it as a discloseable transaction that must be publicly announced. By deploying surplus cash into a short-term, capital-protected instrument, Immunotech seeks incremental yield while maintaining liquidity, signaling a conservative treasury strategy that may modestly enhance interest income without materially altering its core biopharmaceutical operations.
The most recent analyst rating on (HK:6978) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Immunotech Biopharm Ltd stock, see the HK:6978 Stock Forecast page.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a Hong Kong–listed biopharmaceutical company focused on developing and commercializing innovative immunotherapy products. The group operates in the healthcare and life sciences sector, targeting treatments driven by advanced biological technologies for domestic and international markets.
Average Trading Volume: 825,820
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.63B
For an in-depth examination of 6978 stock, go to TipRanks’ Overview page.